The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has uncovered what it calls the 'world's first large-scale illegal manufacturing facility' for weight-loss injections, seizing 2,000 pre-filled pens and £20,000 in cash from a Northampton warehouse. The raid signals escalating regulatory action against unlicensed GLP-1 production, a critical concern for overseas buyers sourcing injectables from legitimate supply chains.
Raid details and scale
In October 2025, the MHRA, supported by Northamptonshire Police, raided a warehouse on Moulton Park industrial estate in Northampton. Officers described the operation as 'large' and 'sophisticated,' seizing 2,000 pre-filled injectable pens and £20,000 in cash. The agency believes this is the first illegal manufacturing facility of its kind globally, where criminals created their own brand rather than producing counterfeit versions of legitimate products.
Products seized and risks
The seized jabs contained tirzepatide and retatrutide. Tirzepatide, sold under the brand Mounjaro by Eli Lilly, is approved in the UK but must be prescribed by a medical professional and produced in a licensed lab. Retatrutide is still in clinical trials and not approved in the US or UK. The MHRA warned that jabs from non-clinical sources offer 'no guarantees about what they contain' and 'may even be contaminated with toxic substances.'
Organized crime and online sales
Andy Morling, head of the MHRA's criminal enforcement unit, said the operation is linked to an organized criminal network. The seized products were branded 'Alluvi Healthcare,' with multiple websites and Telegram accounts selling them as 'research and development' formulas. The BBC conducted a test purchase from an Alluvi website, but the jab never arrived. Morling noted his team has taken down over 400 social media posts and websites selling illicit weight-loss jabs.
Regulatory and channel signals
In 2025, the MHRA confiscated 24 million doses of illicit medicines, with weight-loss jabs accounting for less than 1%. However, Morling warned that production and distribution methods may 'evolve' as patents for these drugs expire and cheap generic versions become available. A subsequent raid in February 2026 in Lincolnshire and Nottingham, plus a recent raid at a Northamptonshire country house, are part of the same investigation.
What buyers should watch
For overseas importers and distributors, this case underscores the importance of verifying manufacturing licenses and supply chain integrity. The MHRA's crackdown highlights the risks of sourcing injectables from unverified online channels. Legitimate buyers should ensure their suppliers operate licensed facilities and comply with local regulatory standards to avoid association with illicit operations.
Source: Read the original report | Published: June 02, 2026